Infectious mononucleosis is an infectious illness most commonly caused by primary infection with Epstein–Barr virus (EBV). Its characteristic features are fever, sore throat, and enlarged lymph nodes, often accompanied by pronounced fatigue. The classic illness occurs mainly in adolescents and young adults. Most cases resolve without specific antiviral treatment, although recovery of energy can take longer than resolution of the acute symptoms.
Cause and transmission
EBV is a member of the herpesvirus family. It is widespread worldwide, and most adults have evidence of previous infection. Infection acquired in early childhood is frequently asymptomatic or produces a nonspecific illness; primary infection during adolescence or adulthood is more likely to cause recognizable mononucleosis.
Transmission occurs chiefly through saliva, including through kissing or sharing saliva-contaminated objects. The nickname “kissing disease” describes one route of transmission but does not encompass all exposure. Transmission through blood products or transplanted organs is also possible.
The incubation period is typically about four to six weeks. EBV can be shed before symptoms develop and for months afterward. Following primary infection, the virus persists for life in a latent state and may be intermittently shed without symptoms. Consequently, the period of infectiousness cannot be defined simply by the presence or absence of illness.
Cytomegalovirus and several other infections can produce a mononucleosis-like syndrome. In clinical usage, “infectious mononucleosis” most often denotes EBV-associated disease, whereas “mononucleosis syndrome” may refer more broadly to similar presentations.
Disease mechanism
EBV infects B lymphocytes, which are cells of the immune system. Much of the acute illness reflects the immune response to infected cells, including expansion of activated T lymphocytes.
The name refers to an increase in mononuclear white blood cells in circulating blood. The conspicuous “atypical lymphocytes” seen on a blood smear are predominantly activated T cells rather than the EBV-infected B cells themselves. These changes can support the diagnosis but are not exclusive to this infection.
Clinical features and course
Symptoms may begin with malaise, reduced appetite, and fatigue, followed by fever and pharyngitis. The tonsils can become markedly enlarged and develop an exudate. Enlarged nodes along the back of the neck are especially characteristic, although lymph-node enlargement may be more widespread.
Other findings include:
- Enlargement of the spleen, which may not be detectable on examination.
- Mild liver involvement, commonly reflected by elevated liver enzymes; visible jaundice is less common.
- Small red spots on the palate.
- A rash, either as part of the illness or in association with medication exposure.
A widespread rash can occur when amoxicillin or ampicillin is administered during EBV-associated mononucleosis. Such a rash does not, by itself, establish a persistent penicillin allergy, although genuine drug hypersensitivity can occur.
The acute illness commonly improves within two to four weeks. Fatigue may persist for several additional weeks or, in some cases, months. Young children often have less typical symptoms, while older adults may have less prominent pharyngitis and lymph-node enlargement.
Diagnosis
Diagnosis combines the clinical presentation with laboratory findings. A complete blood count may show an increased proportion of lymphocytes and atypical lymphocytes. Liver enzyme abnormalities are common but nonspecific.
Heterophile antibody testing
Rapid heterophile antibody tests, often called Monospot tests, detect antibodies associated with the syndrome rather than antibodies directed specifically against EBV. Their limitations include false-negative results early in illness and reduced sensitivity in young children. False-positive results are also possible. A negative test therefore does not exclude mononucleosis, and a positive result does not definitively establish EBV as the cause.
EBV-specific testing
EBV-specific antibody testing can distinguish recent from past infection:
- Viral capsid antigen IgM usually appears early and generally disappears within several weeks.
- Viral capsid antigen IgG appears during acute infection and usually persists for life.
- EBV nuclear antigen antibodies generally become detectable several months after symptom onset and usually persist.
Viral capsid antigen IgM in the absence of EBV nuclear antigen antibodies supports primary infection. Antibodies to both viral capsid antigen IgG and EBV nuclear antigen generally indicate past infection. Persistently high antibody levels alone do not establish active disease.
Differential diagnosis
The differential diagnosis includes cytomegalovirus infection, streptococcal pharyngitis, toxoplasmosis, and acute HIV infection. These conditions can overlap clinically but require different laboratory approaches.
Management
Management is primarily supportive, addressing hydration, fever, pain, and temporary functional limitations. Antibiotics do not treat EBV infection, although they may be used for a separately established bacterial infection.
Routine treatment with an antiviral drug has not shown a clear clinical benefit in uncomplicated infectious mononucleosis. Corticosteroids are not routine treatment either; their use is generally reserved for selected severe complications, such as impending airway obstruction or significant immune-mediated blood disorders.
Because splenic enlargement increases vulnerability to injury, temporary restriction of contact sports and strenuous exertion is an established component of clinical management. Return-to-activity decisions account for time since symptom onset, clinical recovery, and the type of activity. Ultrasonography can measure spleen size, but variation in normal size limits its ability to determine when rupture risk has disappeared.
Complications and longer-term distinctions
Serious complications are uncommon. They include splenic rupture, upper-airway obstruction from tonsillar swelling, immune-mediated destruction of red blood cells, and markedly reduced platelet counts. Neurological and cardiac complications are rare.
Prolonged fatigue after the acute illness does not by itself indicate continued active EBV disease. Chronic active EBV disease is a distinct, rare disorder involving persistent systemic illness and abnormal EBV-infected lymphocytes, rather than simply slow recovery from mononucleosis.
EBV is associated with certain malignancies, including some forms of lymphoma, but infectious mononucleosis is not itself cancer. Most people with EBV infection do not develop an EBV-associated malignancy.
Prevention
No licensed vaccine specifically prevents EBV infection. Prevention efforts focus on limiting exposure to saliva, but asymptomatic shedding and the widespread prevalence of the virus make complete prevention difficult. Recovery from mononucleosis does not eliminate lifelong latent EBV infection.